Business
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson’s disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform across multiple therapeutic modalitiesTwo new seasoned biotech leaders added to the Board of Directors HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization
About this update from Serina Therapeutics, Inc.
[{"type":"image","alt":"Serina Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Serina Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/f5ef3cecb8662785323a6a370007d6d1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vVhesNODR8eRh4qa0Kn9PQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f5ef3cecb8662785323a6a370007d6d1","width":300,"height":84}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson’s disease in Q4 2025","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened balance sheet with recent financing","length":48,"tagName":"p"}]},{"val":[{"type":"text","content":"Advancing innovative POZ Platform across multiple therapeutic modalities","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Two new seasoned biotech leaders added to the Board of Directors","length":64,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":298,"olType":false},{"type":"text","content":"HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2025, along with recent business highlights.","length":338,"tagName":"p"},{"type":"text","content":""We are energized by the substantial progress and strengthened foundation we've achieved in recent months. Our partnership with Enable Injections, combined with our proprietary POZ optimization technology, continues to advance SER-252 toward a differentiated product profile and potential best-in-class therapy for advanced Parkinson’s care. With new capital infusions in the first quarter and April from strategic investors, we remain focused on reaching key milestones, including dosing the first patient in our Phase 1b clinical trial by the fourth quarter of this year," said Steve Ledger, CEO of Serina Therapeutics. "Importantly, we are dedicated to expanding the impact of our POZ Platform and remain committed to pushing the boundaries of our platform’s potenti...